Thank you (Operator Instructions) Our first question comes from George Staphos with Bank of America Merrill Lynch. You may begin.
Thanks, operator. Hi everyone, good morning. Thanks for the details on the quarter. Mike, first question for you. You mentioned the new IV bag tubing and that sounds like an interesting idea. What other investments do you expect we'll see that you can obviously comment on -- in this kind of forum and what kind of -- I don't know what the right phrasing would be, but payback or time to see incrementally better performance in healthcare should we expect from those investments. And I had a couple of quick follow-ons?
Excellent George, good morning. As far as investments, we're investing in core products to our technology space across the board. So printer capabilities that will directly enhance all of our other product platforms and throughout our different product lines, I think the key differentiation is -- today, you can look at every one of our major product lines and see that not only do we have a solid pipeline, but we will be introducing products in a standardized cadence in the next few quarters. Now, how long does that take to really change the marketplace, depending on the product set, it can be six months to 2.5 to three years, depending on the ramp up of the products. So it is very product and market segment and customer dependent. But overall, it will give us a good strong cadence of growth as we move forward in the future years.
Mike, if you wanted to add a little bit of additional color to the extent possible, relative to healthcare, kind of the same question, where are you investing, again, you mentioned that new tubing and how long do you think it would take to see improved performance. I'm guessing it would -- that would be more towards the larger end, if you will, the spectrum 2.5 years in terms of payback, but your thoughts?
It does take a little longer in the medical space for adoption. One of the real reasons is understandably in medical applications, the risk for them is higher. So they're more careful about introducing the products. But you can assume that our product sets are looking at -- making it easier and more reliable for our customers to properly take care of their patient sets. So any time we take a look at a product, we want to make sure that we're adding to reliability, reducing their cost profile and improving their performance profile.
Okay -- Mike, thanks for that. One last one, I'll turn it over. I mean, you gave us your guidance factors, but are there any particular issues or things we should focus on from where we sit that would indicate whether you'd be at the lower end or higher end of your range, implicit for the fourth quarter. And then what effect do you think you're getting right now in terms of the